Link: Accelr8 Announces Pilot Study Completion for Rapid MRSA Identification
According to David Howson, Accelr8’s president, "we’re making rapid progress in our studies on identifying organisms that belong in any of the three major drug resistance categories that are most difficult to treat in the ICU. Each of the three categories requires a two-stage study. We expect to complete expanded studies on large collections of bacterial strains and present them to the medical and scientific communities this year. The May presentation is the first in this series, and we are very pleased with the results."
"As far as we can determine, we remain alone in developing a practical diagnostic solution that eliminates bacterial culturing. Within the diagnostics industry, recent acquisitions and new product announcements related to MRSA address important applications in screening carriers of dangerous bacteria, but not in diagnosing active infections. The urgent problem of delayed diagnosis of actual infections remains unaddressed. Most of the new rapid methods for screening depend on specific conditions, such as the existence of a single gene responsible for resistance. In contrast, our methods allow direct adaptation to the multiple species and complex mechanisms of resistance necessary to support clinical diagnoses. Even so, the speed of our methods even exceeds that of most rapid screening tests," Howson concluded.
Further information about rapid bacterial analysis is available on the company’s Web site at http://www.accelr8.com/
